PART I . Overview Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases. We are advancing a pipeline in which we have matched investigational therapies with diseases for which we believe these therapies can make the gre...
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001193125-26-086645 | EDGAR | 99K words |
| 2025-03-04 | 2024-12-31 | 0000950170-25-031309 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018447 | EDGAR | — |
| 2023-03-13 | 2022-12-31 | 0000950170-23-007609 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0000950170-22-005157 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-336682 | EDGAR | — |
| 2025-11-06 | 2025-09-30 | 0001193125-25-268059 | EDGAR | 72K words |
| 2025-08-07 | 2025-06-30 | 0001193125-25-174948 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066363 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-122833 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093311 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056269 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061516 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041335 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021369 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024465 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016883 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-336670 | EDGAR | — |
| 2026-03-24 | 0001193125-26-120691 | EDGAR | 7K words |
| 2026-03-03 | 0001193125-26-086629 | EDGAR | — |
| 2026-01-08 | 0001193125-26-006991 | EDGAR | — |
| 2025-11-06 | 0001193125-25-268043 | EDGAR | — |
| 2025-09-10 | 0001193125-25-200159 | EDGAR | — |
| 2025-08-27 | 0001193125-25-189109 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104546 | EDGAR | — |
| 2025-06-05 | 0001193125-25-135860 | EDGAR | — |
| 2025-05-08 | 0000950170-25-066355 | EDGAR | — |
79 total filings indexed. 52 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001658551 |
| Ticker | AMLX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.amylyx.com |
| Listed | 2022-01-07 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/AMLX (~200 tokens, structured JSON with cryptographic provenance)